|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental table 1 Baseline and procedural characteristics and laboratory data in patients with critical limb ischemia** | | | | | | | |
|  | **NLR < 5** | | **NLR ≥ 5** | | | **P** | |
|  | **N = 104** | | **N = 91** | | |  | |
| **Age (years)** | **74.2** | **(12.0)** | | **73.7** | **(11.1)** | | **0.755** |
| **Male gender** | **55** | **52.9%** | | **46** | **50.5%** | | **0.745** |
| **Body mass index (kg/m2)** | **23.5** | **(3.8)** | | **23.4** | **(4.6)** | | **0.916** |
| **Heart rate at baseline (beats per minute)** | **84.8** | **(15.4)** | | **92.1** | **(19.6)** | | **0.004** |
| **Systolic BP at baseline (mm Hg)** | **148.0** | **(31.5)** | | **146.6** | **(31.9)** | | **0.745** |
| **Diastolic BP at baseline (mm Hg)** | **73.3** | **(12.8)** | | **77.3** | **(16.0)** | | **0.051** |
| **Current/past smoker** | **28** | **26.9%** | | **18** | **19.8%** | | **0.241** |
| **Alcohol intake** | **30** | **28.8%** | | **25** | **27.5%** | | **0.874** |
| **Family history of premature CAD** | **1** | **1.0%** | | **1** | **1.5%** | | **0.924** |
| **History of hypertension** | **75** | **72.1%** | | **54** | **59.3%** | | **0.06** |
| **History of diabetes mellitus** | **74** | **71.2%** | | **60** | **65.9%** | | **0.433** |
| **History of insulin use** | **15** | **14.4%** | | **10** | **11.0%** | | **0.474** |
| **History of dyslipidemia** | **17** | **16.3%** | | **16** | **17.6%** | | **0.818** |
| **Normal kidney function** | **64** | **61.5%** | | **59** | **64.8%** | | **0.653** |
| **Chronic kidney disease** | **20** | **19.2%** | | **13** | **14.3%** | |  |
| **End-stage renal disease** | **20** | **19.2%** | | **19** | **20.9%** | |  |
| **History of CAD** | **40** | **38.5%** | | **35** | **38.5%** | | **1** |
| **History of old myocardial infarction** | **7** | **6.7%** | | **6** | **6.6%** | | **0.969** |
| **History of atrial fibrillation** | **17** | **16.3%** | | **9** | **9.9%** | | **0.186** |
| **History of chronic heart failure** | **23** | **22.2%** | | **19** | **20.8%** | | **0.943** |
| **NYHA class I** | **6** | **58.0%** | | **4** | **4.4%** | | **0.432** |
| **NYHA class II** | **4** | **3.8%** | | **8** | **8.8%** | | **0.432** |
| **NYHA class III** | **9** | **8.7%** | | **6** | **6.6%** | | **0.432** |
| **NYHA class IV** | **4** | **3.8%** | | **1** | **1.1%** | | **0.432** |
| **History of carotid artery stenosis** | **3** | **2.9%** | | **0** | **0.0%** | | **0.103** |
| **History of ischemic stroke** | **20** | **19.2%** | | **14** | **15.4%** | | **0.48** |
| **Ongoing Cancer** | **8** | **7.7%** | | **4** | **4.4%** | | **0.339** |
| **History of amputation** |  |  | |  |  | | **0.500** |
| **Above-knee amputation** | **2** | **1.9%** | | **4** | **4.4%** | |  |
| **Below-knee amputation** | **2** | **1.9%** | | **1** | **1.1%** | |  |
| **Forefoot amputation** | **2** | **1.9%** | | **2** | **2.2%** | |  |
| **Presented with acute ischemic limb** | **8** | **7.7%** | | **20** | **22.0%** | | **0.005** |
| **Rutherford classification** |  |  | |  |  | | **0.009** |
| **class IV** | **37** | **35.6%** | | **16** | **17.6%** | |  |
| **class V** | **63** | **60.6%** | | **66** | **72.5%** | |  |
| **class VI** | **4** | **3.8%** | | **9** | **9.9%** | |  |
| **Laboratory data** |  |  | |  |  | |  |
| **Total cholesterol (mg/dl)** | **162.9** | **(46.4)** | | **147.9** | **(47.7)** | | **0.033** |
| **High-density lipoprotein cholesterol (mg/dl)** | **42.8** | **(19.7)** | | **37.3** | **(17.0)** | | **0.230** |
| **Low-density lipoprotein cholesterol (mg/dl)** | **94.2** | **(36.3)** | | **89.9** | **(38.6)** | | **0.637** |
| **Triglyceride (mg/dl)** | **153.4** | **(127.9)** | | **135.6** | **(91.0)** | | **0.290** |
| **Fasting glucose (mg/dl)** | **178.4** | **(92.1)** | | **181.5** | **(118.4)** | | **0.836** |
| **Glycosylated hemoglobin (%)** | **7.4** | **(1.7)** | | **7.6** | **(2.1)** | | **0.626** |
| **Creatinine (mg/dl)** | **3.1** | **(2.7)** | | **3.8** | **(3.8)** | | **0.140** |
| **Alanine transaminase (IU/L)** | **17.9** | **(10.2)** | | **28.6** | **(29.1)** | | **0.001** |
| **Uric acid (mg/dl)** | **5.5** | **(2.1)** | | **6.1** | **(2.7)** | | **0.151** |
| **White blood cell count 103 / *u*L** | **7.2** | **(2.6)** | | **12.7** | **(5.6)** | | **<0.001** |
| **Neutrophil ratio (%)** | **61.5** | **(11.5)** | | **82.0** | **(6.2)** | | **<0.001** |
| **Lymphocyte ratio (%)** | **23.1** | **(6.9)** | | **8.1** | **(3.6)** | | **<0.001** |
| **NLR** | **2.9** | **(1.0)** | | **14.2** | **(12.1)** | | **<0.001** |
| **Medication use at baseline** |  |  | |  |  | |  |
| **Aspirin** | **41** | **39.4%** | | **26** | **28.6%** | | **0.111** |
| **Cilostazol** | **57** | **54.8%** | | **33** | **36.3%** | | **0.01** |
| **Clopidogrel** | **23** | **22.1%** | | **30** | **33.0%** | | **0.089** |
| **Pentoxyphylline** | **5** | **4.8%** | | **3** | **3.3%** | | **0.596** |
| **ACEI or ARB** | **6** | **5.8%** | | **3** | **3.3%** | | **0.412** |
| **Beta-blocker** | **21** | **20.2%** | | **14** | **15.4%** | | **0.383** |
| **Calcium channel block** | **20** | **19.2%** | | **19** | **20.9%** | | **0.774** |
| **Statin** | **25** | **24.0%** | | **12** | **13.2%** | | **0.054** |
| **Urate lowering therapy** | **1** | **1.0%** | | **4** | **4.4%** | | **0.13** |

**Values were expressed as number and (standard deviation) or number and percentage.**

**CAD = coronary artery disease; NYHA = New York Heart Association; BP = blood pressure; NLR = neutrophil-lymphocyte ratio; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers.**